Search NASA⌕ Search

SEARCH · Search NASA

Results for “VHH”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

12 records
All sourcesNASA NTRSDOE OSTI
DOE OSTI2023

Molecular recognition requires dimerization of a VHH antibody

Camelid heavy-chain-only antibodies are a unique class of antibody that possesses only a single variable domain (termed VHH) for antigen recognition. Despite their apparent canonical mechanism of target recognition, where a single VHH domain binds a single target, an anti-caffeine VHH has been observed to possess 2:1 stoichiometry. Here, the structure of the anti-caffeine VHH/caffeine complex enabled the generation and biophysical analysis of variants that were used to better understand the role of VHH homodimerization in caffeine recognition. VHH interface mutants and caffeine analogs, which were examined to probe the mechanism of caffeine binding, suggested caffeine recognition is only possible with the VHH dimer species. Correspondingly, in the absence of caffeine, the anti-caffeine VHH was found to form a dimer with a dimerization constant comparable to that observed with VH:VL domains in conventional antibody systems, which was most stable near physiological temperature. While the VHH:VHH dimer structure (at 1.13 Å resolution) is reminiscent of conventional VH:VL heterodimers, the homodimeric VHH possesses a smaller angle of domain interaction, as well as a larger amount of apolar surface area burial. To test the general hypothesis that the short complementarity-determining region-3 (CDR3) may help drive VHH:VHH homodimerization, an anti-picloram VHH domain containing a short CDR3 was generated and characterized, which revealed it also existed as dimer species in solution. These results suggest homodimer-driven recognition may represent a more common method of VHH ligand recognition, opening opportunities for novel VHH homodimer affinity reagents and helping to guide their use in chemically induced dimerization applications.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2022

Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies

Toxin A (TcdA) and toxin B (TcdB) are two key virulence factors secreted by Clostridioides difficile, which is listed as an urgent threat by the CDC. These two large homologous exotoxins are mainly responsible for diseases associated with C. difficile infection (CDI) with symptoms ranging from diarrhea to life threatening pseudomembranous colitis. Single-domain camelid antibodies (VHHs) AH3 and AA6 are two potent antitoxins against TcdA, which when combined with two TcdB-targeting VHHs showed effective protection against both primary and recurrent CDI in animal models. Here, we report the co-crystal structures of AH3 and AA6 when they form complexes with the glucosyltransferase domain (GTD) and a fragment of the delivery and receptor-binding domain (DRBD) of TcdA, respectively. Based on these structures, we find that AH3 binding enhances the overall stability of the GTD and interferes with its unfolding at acidic pH, and AA6 may inhibit the pH-dependent conformational changes in the DRBD that is necessary for pore formation of TcdA. These studies reveal two functionally critical epitopes on TcdA and shed new insights into neutralizing mechanisms and potential development of epitope-focused vaccines against TcdA.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2020

Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells

Botulinum neurotoxin serotype E (BoNT/E) is one of the major causes of human botulism, which is a life-threatening disease caused by flaccid paralysis of muscles. After receptor-mediated toxin internalization into motor neurons, the translocation domain (HN) of BoNT/E transforms into a protein channel upon vesicle acidification in endosomes and delivers its protease domain (LC) across membrane to enter the neuronal cytosol. It is believed that the rapid onset of BoNT/E intoxication compared to other BoNT serotypes is related to its swift internalization and translocation. We recently identified two neutralizing single-domain camelid antibodies (VHHs) against BoNT/E1 termed JLE-E5 and JLE-E9. Here, we report the crystal structures of these two VHHs bound to the LCHN domain of BoNT/E1. The structures reveal that these VHHs recognize two distinct epitopes that are partially overlapping with the putative transmembrane regions on HN, and therefore could physically block membrane association of BoNT/E1. This is confirmed by our in vitro studies, which show that these VHHs inhibit the structural change of BoNT/E1 at acidic pH and interfere with BoNT/E1 association with lipid vesicles. Therefore, these two VHHs neutralize BoNT/E1 by preventing the transmembrane delivery of LC. Furthermore, structure-based sequence analyses show that the 3-dimensional epitopes of these two VHHs are largely conserved across many BoNT/E subtypes, suggesting a broad-spectrum protection against the BoNT/E family. In summary, this work improves our understanding of the membrane translocation mechanism of BoNT/E and paves the way for developing VHHs as diagnostics or therapeutics for the treatment of BoNT/E intoxication.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2025

VHH antibody loop guides design of a synthetic macrocyclic peptide that potently blocks influenza virus membrane fusion

Abstract Miniaturizing biologically complex structural motifs to produce synthetic functional mimetics holds significant promise for development of new therapeutic modalities. Here, we demonstrate a unique approach using the key binding loop of the single variable domain of a heavy chain (V H H) llama antibody as a starting point for peptide design. V H H antibodies of camelids and sharks generally have longer, but more ligand-efficient complementarity determining region 3 (CDR3) loops and are relatively stable structures. We harnessed these attributes as templates for design of a series of synthetic macrocyclic peptides. The designed peptides exhibit nanomolar binding to influenza hemagglutinin (HA) and heterosubtypic in vitro neutralization breadth against influenza A viruses by inhibiting the low pH mediated HA conformational changes that lead to membrane fusion. X-ray structures of peptide-HA complexes reveal high structural mimicry with the parent V H H antibody. One such macrocycle peptide candidate is promising for further development of broad protection against influenza A group 1 viruses.

Kadam, Rameshwar U.↗
DOE OSTI2025

Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling

Interleukin (IL)-23 is a validated therapeutic target in inflammatory bowel disease. While antibodies targeting IL23 demonstrate clinical efficacy, they face challenges such as high costs, safety risks, and the necessity of parenteral administration. Here, we present a workflow to simultaneously enhance the affinity and protease stability of an inhibitory anti-IL23R VHH for oral use. Cocrystal structure analysis reveals that the anti-IL23R VHH employs both CDR and framework residues to achieve picomolar affinity for IL23R. The engineered VHH remains stable for over 8 h in intestinal fluid and 24 h in fecal samples. Oral administration of this VHH achieves deep pathway inhibition in a murine colitis model. Furthermore, a single pill provides sustained IL23R inhibition in nonhuman primate blood for over 24 h. With high potency, gut stability, high production yield, and favorable drug-like properties, oral VHHs offer a promising approach for inflammatory bowel diseases.

Science & Technology - Other Topics↗
DOE OSTI2023

Search for Higgs boson pair production in association with a vector boson in pp collisions at $\sqrt{s}=13\,\text {TeV}$ with the ATLAS detector

This paper reports a search for Higgs boson pair (hh) production in association with a vector boson ($W\; {\text {o}r}\; Z$) using 139 fb –1 of proton–proton collision data at $\sqrt{s}=13\,\text {TeV}$ recorded with the ATLAS detector at the Large Hadron Collider. The search is performed in final states in which the vector boson decays leptonically ($W\rightarrow \ell \nu ,\, Z\rightarrow \ell \ell ,\nu \nu$ with $\ell =e, \mu$) and the Higgs bosons each decay into a pair of b-quarks. It targets Vhh signals from both non-resonant hh production, present in the Standard Model (SM), and resonant hh production, as predicted in some SM extensions. A 95% confidence-level upper limit of 183 (87) times the SM cross-section is observed (expected) for non-resonant Vhh production when assuming the kinematics are as expected in the SM. Constraints are also placed on Higgs boson coupling modifiers. For the resonant search, upper limits on the production cross-sections are derived for two specific models: one is the production of a vector boson along with a neutral heavy scalar resonance H, in the mass range 260–1000 GeV, that decays into hh, and the other is the production of a heavier neutral pseudoscalar resonance A that decays into a Z boson and H boson, where the A boson mass is 360–800 GeV and the H boson mass is 260–400 GeV. Constraints are also derived in the parameter space of two-Higgs-doublet models.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
DOE OSTI2021

Erratum to: Search for the HH → $ b\overline{b}b\overline{b} $ process via vector-boson fusion production using proton-proton collisions at $ \sqrt{s} $ = 13 TeV with the ATLAS detector

One correction is noted for the paper. A wrong cross-section was used for the theory prediction in figure 6 due to not taking into account the VHH contamination properly in the rescaling formula for the signal samples. The change in the theory prediction leads to stricter exclusion limits on the di-vector-boson–di-Higgs-boson coupling modifier κ 2V . The observed excluded region corresponds to κ 2V < –0.43 and κ 2V > 2.56, while the expected exclusion is κ 2V < –0.55 and κ 2V > 2.72. Erratum JHEP 01 (2021) 145 fixed the description in the text but contains the uncorrected figure. The correct figure is shown in the new erratum.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
DOE OSTI2024

Search for Higgs boson pair production with one associated vector boson in proton-proton collisions at $ \sqrt{s} $ = 13 TeV

A search for Higgs boson pair (HH) production in association with a vector boson V (W or Z boson) is presented. The search is based on proton-proton collision data at a center-of-mass energy of 13 TeV, collected with the CMS detector at the LHC, corresponding to an integrated luminosity of 138 fb$^{−1}$. Both hadronic and leptonic decays of V bosons are used. The leptons considered are electrons, muons, and neutrinos. The HH production is searched for in the $ \textrm{b}\overline{\textrm{b}}\textrm{b}\overline{\textrm{b}} $ decay channel. An observed (expected) upper limit at 95% confidence level of VHH production cross section is set at 294 (124) times the standard model prediction. Constraints are also set on the modifiers of the Higgs boson trilinear self-coupling, k$_{λ}$, assuming k$_{2V}$ = 1, and vice versa on the coupling of two Higgs bosons with two vector bosons, k$_{2V}$. The observed (expected) 95% confidence intervals of these coupling modifiers are −37.7 < k$_{λ}$ < 37.2 (−30.1 < k$_{λ}$ < 28.9) and −12.2 < k$_{2V}$ < 13.5 (−7.2 < k$_{2V}$ < 8.9), respectively.[graphic not available: see fulltext]

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
DOE OSTI2022

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Botulinum neurotoxins (BoNTs) are among the deadliest of bacterial toxins. BoNT serotype A and B in particular pose the most serious threat to humans because of their high potency and persistence. To date, there is no effective treatment for late post-exposure therapy of botulism patients. Here, we aim to develop single-domain variable heavy-chain (VHH) antibodies targeting the protease domains (also known as the light chain, LC) of BoNT/A and BoNT/B as antidotes for post-intoxication treatments. Using a combination of X-ray crystallography and biochemical assays, we investigated the structures and inhibition mechanisms of a dozen unique VHHs that recognize four and three non-overlapping epitopes on the LC of BoNT/A and BoNT/B, respectively. We show that the VHHs that inhibit the LC activity occupy the extended substrate-recognition exosites or the cleavage pocket of LC/A or LC/B and thus block substrate binding. Notably, we identified several VHHs that recognize highly conserved epitopes across BoNT/A or BoNT/B subtypes, suggesting that these VHHs exhibit broad subtype efficacy. Further, we identify two novel conformations of the full-length LC/A, that could aid future development of inhibitors against BoNT/A. Our studies lay the foundation for structure-based engineering of protein- or peptide-based BoNT inhibitors with enhanced potencies and cross-subtypes properties.

59 BASIC BIOLOGICAL SCIENCES↗